Q2 saw robust revenue and order intake growth, with improved EBITDA and a strengthened cash position. The order book is healthy, driven by MedTech demand, and management expects sustained profitability and growth, supported by new partnerships and a focus on AI and robotics.Based on Mentice AB [MNT…
Net sales and order intake saw strong double-digit growth in Q2 2026, driven by the Medical Device Industry segment and robust performance in EMEA and APAC. EBITDA and net income improved significantly, supported by major new orders and operational efficiencies.Original document: Mentice AB [MNTC…
Mentice (publ) issues a correction to the Press Release published on June 29th at 18:00. The correction concerns that the Press Release did not include the MAR label with reference to the EU Market Abuse Regulation (MAR). Apart from this the Press Release remains unchanged.Mentice AB (publ), a glob…
Mentice AB OMXSTO:MNTC:
Mentice AB (publ), a globally recognized leader in simulation solutions for image-guided therapies, today announced the receipt of two orders in total value of $2.4M from one of the world’s top 20 medical technology companies. This valued long-term customer continues to rely on Mentice advanced sim…
